(EMAILWIRE.COM, November 14, 2018 ) The innovation of gene testing technologies for the development of personalized medicine for cardiovascular diseases is one of the major trends in the market. Due to the reduction in the cost of gene testing, patients can screen for their predisposition for specific cardiovascular diseases. Gene testing helps in the development of personalized pharmacogenomics agents and improved patient monitoring efforts for cardiovascular disorders and detect them before an onset of acute care episodes.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL CARDIOVASCULAR DRUGS MARKET TO GROW TO $139 BILLION BY 2021
North America was the largest region in the cardiovascular drugs market in 2017, accounting for approximately two-fifth of the market share. This can be attributed to the high level of healthcare facilities, awareness among people, and GDP of the country.
Order the report at: http://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report-2018
According to The Business Research Companys Consultant, Nitin Gianchandani, the Food and Drug Administration (FDA) in the USA has approved new drugs for treatment of chronic heart failure, a cardiovascular disorder caused by an inadequate cardiac output (ability of the heart to pump blood). In April 2015, the Food and Drug Administration (FDA) in the US approved Corlanor, a chronic heart failure drug that can be used by patients with symptoms of stable heart failure, and a normal heartbeat. Similarly, in July 2015, FDA approved Entresto that can be used
to reduce the risk of cardiovascular death and heart failure hospitalization.
Download a sample of the report at: http://www.thebusinessresearchcompany.com/sample.aspx?id=271&type=smp
Merck & Co. was the largest company in the cardiovascular drugs market with a 7.57% market share in 2017, generating revenues of $9.8 billion for the financial year 2016. Merck & Co.s growth strategy is to enhance its global cardiovascular business by expanding its research facilities. In January 2017, the company started construction of its new research facility in South San Francisco which is expected to be ready by 2019. This facility is expected to have nine stories and 290,000 square feet of research and office space that will be used for research on cardiovascular, metabolic and renal diseases. Merck & Co. is also actively recruiting scientists for its new research facility.
The cardiovascular drugs market covers drugs used to treat conditions that affect the heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and Angiotensin II receptor antagonists, and hypolipidemic drugs such as fibric acid derivatives and bile acid binding resins.
Cardiovascular Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company.
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company’s management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: http://in.linkedin.com/company/the-business-research-company
Marketing TBRC
+91 8897263534
Marketing@tbrc.info
Source: EmailWire.Com 
